Hemophilia Treatment Market – A Significant Management for Hemophilic Patients
Hemophilia, a genetic bleeding disorder, in which an individual lacks or has low levels of proteins such as clotting factor, factor VIII. There are around 13 types of clotting factors that work with blood platelets to help in clotting. There are three forms of hemophilia – A, B, and C. Hemophilia A is the most common form and is caused due to deficiency of factor VIII. Hemophilia B occurs due to deficiency of factor IX, and Hemophilia C is caused due to factor XI deficiency.
Novel product launches by market players and product approvals in the hemophilia treatment are expected to boost growth of the market over the forecast period. For instance, in June 2019, Novo Nordisk received marketing authorization from the European Commission for ‘Esperoct’ in Europe. Esperoct is the brand name for turoctocog alfa pegol, N8-GP, indicated for surgical procedures in adolescents and adults with hemophilia A (congenital factor VIII deficiency). Moreover, in April 2019, Roche Products India Pvt. Ltd launched hemophilia A drug Emicizumab, branded as Hemlibra in India. It is indicated for prophylactic treatment for reducing frequency of bleeding episodes in patients with hemophilia A, through Factor VIII inhibitors.
To Gain More Insights into the Hemophilia Treatment Market, Browse Summary of the Research Report – https://www.coherentmarketinsights.com/market-insight/hemophilia-treatment-market-2012
Furthermore, increasing government initiatives to promote awareness about hemophilia treatment among the populace is expected to propel growth of the market over the forecast period. For instance, the National Bleeding Authority (NBA) provides funding to AHCDO (Australian Hemophilia Center Directors’ Organization) for treatment and management of hemophilia A (Factor VIII Deficiency) in Australia.
The global hemophilia treatment market was valued at US$ 11,474.3 million in 2018, and is expected to exhibit a CAGR of 5.9% over the forecast period (2019-2027).
Key Players
Major players operating in the global hemophilia treatment market include Takeda Pharmaceutical Co., Ltd., Sanofi S.A., Octapharma AG, Swedish Orphan Biovitrum AB, Baxter International Inc., Biogen Inc., Bayer AG, CSL Behring, Ferring B.V., Pfizer, Inc., Kedrion, Novo Nordisk A/S, and F. Hoffmann-La Roche AG.
“We Do Offer Sample of this report. Kindly go through the follow information in order to access the report.”
Note- This report sample includes:
– Brief Introduction to the research report.
– Table of Contents (Scope covered as a part of the study)
– Top players in the market
– Research framework (structure of the report)
– Research methodology adopted by Coherent Market Insights
Request A Sample Copy – Hemophilia Treatment Market Report Click here: https://www.coherentmarketinsights.com/insight/request-sample/2012
Rising cases of bleeding disorders is expected to boost growth of the global hemophilia treatment market
The global hemophilia treatment market is expected to witness significant growth, owing to rising incidence of hemophilia or bleeding disorders. For instance, according to the Australian Bleeding Disorders Registry, in 2015, there were around 4,941 patients who suffered from common hereditary bleeding disorders, out of which 2,301 patients were diagnosed with hemophilia A, and 548 patients were diagnosed with hemophilia B in Australia. Thus, increasing prevalence of hemophilia is expected to drive demand for hemophilia treatment over the forecast period. Moreover, increasing demand for efficient therapeutics for treatment of factor VIII deficiency from emerging economies such as India is expected to drive the market growth over the forecast period. For instance, according to the World Federation of Hemophilia’s 2017 statistics, in India, around 18,353 people were diagnosed with hemophilia in 2016.
Increasing healthcare expenditure and reimbursement policies in respective countries or regions are expected to drive the market growth
North America is expected to hold a dominant position in the global hemophilia treatment market, owing to increasing strategic partnerships and collaborations, which are expected to drive growth of the North America market growth over the forecast period. For instance, in April 2014, Biogen, Inc. signed a license agreement with Amunix Operating Inc., a California-based biotechnology company, for research and development of novel, fully-recombinant Factor VIII products with improved therapeutic properties. Under the license agreement, Biogen is focused on development of XTENylated Factor VIII products for treatment of factor VIII deficiency.
Note: Access insightful study with over 150+ pages, list of tables & figures, profiling 20+ companies.
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/2012
Moreover, Asia Pacific is expected to witness second largest growth in the global hemophilia treatment market, owing to rising favorable reimbursement policies for hemophilia treatment in economies such as China. For instance, according to the report published by the China Ministry of Health in 2012, outpatient hemophilia treatment is covered by health insurance schemes in over 80% of the cities in China. Moreover, annual reimbursement is usually accounted below US$ 16,000.
Detailed Segmentation:
- Global Hemophilia treatment market, By Product Type:
- Plasma Derived Coagulation Factor Concentrates
- Recombinant Coagulation Factor Concentrates
- Antifibrinolytic Agents
- Desmopressin
- Global Hemophilia treatment market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Hemophilia treatment market, By Region:
- North America
- By Product Type:
- Plasma Derived Coagulation Factor Concentrates
- Recombinant Coagulation Factor Concentrates
- Antifibrinolytic Agents
- Desmopressin
- By Disease Indication:
- Hemophilia A
- Hemophilia B
- Hemophilia C
- By Country:
- U.S.
- Canada
- By Product Type:
- Latin America
- By Product Type:
- By Disease Indication:
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Product Type:
- By Disease Indication:
- By Country:
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Product Type:
- By Disease Indication:
- By Country:
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Pakistan
- Rest of Asia Pacific
- Middle East
- By Product Type:
- By Disease Indication:
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Product Type:
- By Disease Indication:
- By Country:
- North Africa
- Central Africa
- South Africa
- North America
Browse Press Release: http://bit.ly/2SSj6em
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
